Iovance raises 2026 revenue guidance to $410M-$420M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. SMCI
8. RTX
9. COF
10. GOOGL

Go back to Iovance raises 2026 revenue guidance to $410M-$420M

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

September 29, 2026 7:00 AM EDT

New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million

Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook

PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today raised its full year 2026 total revenue guidance range to $410 to $420 million, driven by strong U.S. demand for Amtagvi® (lifileucel) and Proleukin. The midpoint represents an... More